Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University, discusses with host Dr. Maurice Pickard what appears to be a ‘job' that may exploit the underclass in Phase 1 clinical studies. The poor in the studies are less likely to have access to the drugs when approved, which calls the risk/benefit ratio into question. Do for-profit research companies and for-profit Institutional Review Boards provide adequate protection for the rights of the volunteers?
ReachMD
Be part of the knowledge.™Unfair Treatment of Phase I Clinical Trial Subjects
Choose a format
Media formats available:
Facebook Comments